|
1
|
Bradley PJ: Adenoid cystic carcinoma
evaluation and management: Progress with optimism! Curr Opin
Otolaryngol Head Neck Surg. 25:147–153. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Coca-Pelaz A, Rodrigo JP, Bradley PJ,
Vander Poorten V, Triantafyllou A, Hunt JL, Strojan P, Rinaldo A,
Haigentz M Jr, Takes RP, et al: Adenoid cystic carcinoma of the
head and neck - An update. Oral Oncol. 51:652–661. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Castelnuovo P and Turri-Zanoni M: Adenoid
cystic carcinoma. Adv Otorhinolaryngol. 84:197–209. 2020.PubMed/NCBI
|
|
4
|
Gao M, Hao Y, Huang MX, Ma DQ, Luo HY, Gao
Y, Peng X and Yu GY: Clinicopathological study of distant
metastases of salivary adenoid cystic carcinoma. Int J Oral
Maxillofac Implants. 42:923–928. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ma B, Liang LZ, Liao GQ, Liang YJ, Liu HC,
Zheng GS and Su YX: Inhibition of autophagy enhances cisplatin
cytotoxicity in human adenoid cystic carcinoma cells of salivary
glands. J Oral Pathol Med. 42:774–780. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yu J, Tang Z, Gong W, Zhang M and Quan Z:
Isolation and identification of tumor-initiating cell properties in
human gallbladder cancer cell lines using the marker cluster of
differentiation 133. Oncol Lett. 14:7111–7120. 2017.PubMed/NCBI
|
|
7
|
Hermann PC, Huber SL, Herrler T, Aicher A,
Ellwart JW, Guba M, Bruns CJ and Heeschen C: Distinct populations
of cancer stem cells determine tumor growth and metastatic activity
in human pancreatic cancer. Cell Stem Cell. 1:313–323. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li C, Wang C, Xing Y, Zhen J and Ai Z:
CD133 promotes gallbladder carcinoma cell migration through
activating Akt phosphorylation. Oncotarget. 7:17751–17759. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Manoranjan B, Chokshi C, Venugopal C,
Subapanditha M, Savage N, Tatari N, Provias JP, Murty NK, Moffat J,
Doble BW, et al: A CD133-AKT-Wnt signaling axis drives glioblastoma
brain tumor-initiating cells. Oncogene. 39:1590–1599. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lu R, Zhao G, Yang Y, Jiang Z, Cai J and
Hu H: Inhibition of CD133 overcomes cisplatin resistance through
inhibiting PI3K/AKT/mTOR signaling pathway and autophagy in
CD133-positive gastric cancer cells. Technol Cancer Res Treat. Jan
1–2019.(Epub ahead of print). doi: 10.1177/1533033819864311.
View Article : Google Scholar
|
|
11
|
Fayi MA, Alamri A and Rajagopalan P:
IOX-101 Reverses drug resistance through suppression of
Akt/mTOR/NF-κB signaling in cancer stem cell-like, sphere-forming
NSCLC cell. Oncol Res. 28:177–189. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yuan Z, Liang X, Zhan Y, Wang Z, Xu J, Qiu
Y, Wang J, Cao Y, Le VM, Ly HT, et al: Targeting CD133 reverses
drug-resistance via the AKT/NF-κB/MDR1 pathway in colorectal
cancer. Br J Cancer. 122:1342–1353. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Panaccione A, Zhang Y, Ryan M, Moskaluk
CA, Anderson KS, Yarbrough WG and Ivanov SV: MYB fusions and CD
markers as tools for authentication and purification of cancer stem
cells from salivary adenoid cystic carcinoma. Stem Cell Res (Amst).
21:160–166. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang SS, Gao XL, Liu X, Gao SY, Fan YL,
Jiang YP, Ma XR, Jiang J, Feng H, Chen QM, et al: CD133+
cancer stem-like cells promote migration and invasion of salivary
adenoid cystic carcinoma by inducing vasculogenic mimicry
formation. Oncotarget. 7:29051–29062. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Panayotopoulou EG, Müller AK, Börries M,
Busch H, Hu G and Lev S: Targeting of apoptotic pathways by SMAC or
BH3 mimetics distinctly sensitizes paclitaxel-resistant triple
negative breast cancer cells. Oncotarget. 8:45088–45104. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cherifi F, Rambeau A, Johnson A, Florescu
C, Géry B, Babin E and Thariat J: Systemic treatments of metastatic
or locally recurrent adenoid cystic carcinoma of the head and neck,
a systematic review. Bull Cancer. 106:923–938. 2019.(In French).
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qi W, Guo J, Wu S, Su B, Zhang L, Pan J
and Zhang J: Synergistic effect of nanosecond pulsed electric field
combined with low-dose of pingyangmycin on salivary adenoid cystic
carcinoma. Oncol Rep. 31:2220–2228. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vasan N, Baselga J and Hyman DM: A view on
drug resistance in cancer. Nature. 575:299–309. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bi CL, Fang JS, Chen FH, Wang YJ and Wu J:
Chemoresistance of CD133(+) tumor stem cells from human brain
glioma. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 32:568–573. 2007.(In
Chinese). PubMed/NCBI
|
|
21
|
Attia S, Atwan N, Arafa M and Shahin RA:
Expression of CD133 as a cancer stem cell marker in invasive
gastric carcinoma. Pathologica. 111:18–23. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Barzegar Behrooz A, Syahir A and Ahmad S:
CD133: Beyond a cancer stem cell biomarker. J Drug Target.
27:257–269. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Aghajani M, Mansoori B, Mohammadi A,
Asadzadeh Z and Baradaran B: New emerging roles of CD133 in cancer
stem cell: Signaling pathway and miRNA regulation. J Cell Physiol.
234:21642–21661. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jia Q, Zhang X, Deng T and Gao J: Positive
correlation of Oct4 and ABCG2 to chemotherapeutic resistance in
CD90(+)CD133(+) liver cancer stem cells. Cell Reprogram.
15:143–150. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sarvi S, Mackinnon AC, Avlonitis N,
Bradley M, Rintoul RC, Rassl DM, Wang W, Forbes SJ, Gregory CD and
Sethi T: CD133+ cancer stem-like cells in small cell
lung cancer are highly tumorigenic and chemoresistant but sensitive
to a novel neuropeptide antagonist. Cancer Res. 74:1554–1565. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
van Rhenen A, Feller N, Kelder A, Westra
AH, Rombouts E, Zweegman S, van der Pol MA, Waisfisz Q,
Ossenkoppele GJ and Schuurhuis GJ: High stem cell frequency in
acute myeloid leukemia at diagnosis predicts high minimal residual
disease and poor survival. Clin Cancer Res. 11:6520–6527. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bertolini G, Roz L, Perego P, Tortoreto M,
Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S,
et al: Highly tumorigenic lung cancer CD133+ cells
display stem-like features and are spared by cisplatin treatment.
Proc Natl Acad Sci USA. 106:16281–16286. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee TK, Castilho A, Cheung VC, Tang KH, Ma
S and Ng IO: CD24(+) liver tumor-initiating cells drive
self-renewal and tumor initiation through STAT3-mediated NANOG
regulation. Cell Stem Cell. 9:50–63. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kong FB, Deng QM, Deng HQ, Dong CC, Li L,
He CG, Wang XT, Xu S and Mai W: Siva 1 regulates multidrug
resistance of gastric cancer by targeting MDR1 and MRP1 via the
NF-κB pathway. Mol Med Rep. 22:1558–1566. 2020. View Article : Google Scholar : PubMed/NCBI
|
